Behavioral interactions of opioid agonists and antagonists with serotonergic systems.
D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects*; D003216:Conditioning, Operant / Q000187:drug effects; D003496:Cyclazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D016314:Ethylketocyclazocine; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008297:Male; D008711:Metergoline / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009294:Narcotics / Q000494:pharmacology*; D010620:Phenazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D011814:Quipazine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011985:Receptors, Serotonin / Q000187:drug effects*; D012055:Reinforcement Schedule
D009292:Narcotic Antagonists; D009294:Narcotics; D011985:Receptors, Serotonin; D008711:Metergoline; D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine; D009270:Naloxone; D011814:Quipazine; D016314:Ethylketocyclazocine; C012134:SK&F 10047; D008238:Lysergic Acid Diethylamide; D010620:Phenazocine; D003496:Cyclazocine